Literature DB >> 2929853

Ivermectin for human strongyloidiasis and other intestinal helminths.

C Naquira1, G Jimenez, J G Guerra, R Bernal, D R Nalin, D Neu, M Aziz.   

Abstract

Since ivermectin, a mixture of 2 closely related macrocyclic lactones, has proven highly effective against animal intestinal nematodes, trials were undertaken to determine its efficacy against human intestinal nematodes. We tested 110 patients with strongyloidiasis and 90 with enterobiasis; many had other intercurrent intestinal nematode infections. Stool examinations were done before and after patients were given a single dose of oral ivermectin capsules (50, 100, 150, or 200 micrograms/kg body wt); 55 recipients of 100 or 200 micrograms/kg doses received a second identical dose the next day. Kato and saline smears, ethyl acetate concentration, modified Baermann's technique, and Harada-Mori cultures were repeated; cure was defined as complete absence of eggs and/or larvae from stools tested 30 days after dosing. Ivermectin was well tolerated. Overall cure rates at all doses 30 days after therapy averaged 88% for strongyloidiasis, 100% for ascariasis, 85% for trichuriasis, and 85% for enterobiasis. Ancylostoma duodenale and Necator americanus were little affected.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2929853     DOI: 10.4269/ajtmh.1989.40.304

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  29 in total

1.  Effects of annual mass treatment with ivermectin for onchocerciasis on the prevalence of intestinal helminths.

Authors:  Julie Gutman; Emmanuel Emukah; Njideka Okpala; Chinyere Okoro; Andrew Obasi; Emmanuel S Miri; Frank O Richards
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

Review 2.  Anthelminthic agents: some recent developments and their clinical application.

Authors:  G C Cook
Journal:  Postgrad Med J       Date:  1991-01       Impact factor: 2.401

3.  Phase III Clinical Trial to Evaluate Ivermectin in the Reduction of Mansonella ozzardi infection in the Brazilian Amazon.

Authors:  Sergio de Almeida Basano; Juliana de Souza Almeida Aranha Camargo; Gilberto Fontes; Antonieta Relvas Pereira; Jansen Fernandes Medeiros; Mayara Costa de Oliveira Laudisse; Ricardo de Godoi Mattos Ferreira; Luís Marcelo Aranha Camargo
Journal:  Am J Trop Med Hyg       Date:  2018-01-04       Impact factor: 2.345

4.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

Review 5.  Ivermectin. A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis.

Authors:  K L Goa; D McTavish; S P Clissold
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

Review 6.  Strongyloidiasis: a conundrum for gastroenterologists.

Authors:  D I Grove
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

7.  Strongyloidiasis.

Authors:  R G Shidrawi; D Westaby
Journal:  Gut       Date:  1994-12       Impact factor: 23.059

8.  Enterobius vermicularis infection.

Authors:  G C Cook
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

9.  Pulmonary Strongyloidiasis: The Varied Clinical Presentations.

Authors:  Babak Mokhlesi; Oksana Shulzhenko; Prasad S Garimella; Leslie Kuma; Catherine Monti
Journal:  Clin Pulm Med       Date:  2004-01

Review 10.  Human gastrointestinal nematode infections: are new control methods required?

Authors:  Gillian Stepek; David J Buttle; Ian R Duce; Jerzy M Behnke
Journal:  Int J Exp Pathol       Date:  2006-10       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.